
Babesiosis is an important tick-borne parasitic disease with limited therapeutic options. Tafenoquine exhibits potent antibabesial activity, but the metabolic basis underlying its antibabesial activity remains unclear. Here, we investigated metabolic alterations associated with tafenoquine treatment during Babesia microti infection, with a focus on redox regulation. BALB/c mice infected with B. microti were treated with tafenoquine, and serum metabolites were profiled using widely targeted metabolomics. Differential metabolic changes were identified by multivariate and univariate analyses, and redox-related alterations were further evaluated together with biochemical measurements of antioxidant defense and oxidative damage markers. Serum metabolic profiles differed between tafenoquine-treated and untreated infected mice, particularly during the acute infection stage. Redox-related metabolic remodeling was characterized by alterations in metabolites involved in cysteine and methionine metabolism, glutathione metabolism, taurine and related metabolism, and the tricarboxylic acid cycle. Following tafenoquine treatment, superoxide dismutase and glutathione peroxidase activities in serum were lower, whereas malondialdehyde levels were higher, consistent with lipid peroxidation. Together, these metabolomic and biochemical findings are consistent with substantial redox metabolic remodeling associated with tafenoquine treatment during B. microti infection.
Cryptosporidiosis is a major zoonotic diarrheal disease caused by Cryptosporidium spp. and is associated with severe diarrhea, growth faltering, malnutrition, and mortality in young children, immunocompromised individuals, and neonatal ruminants. Treatment options remain limited, and nitazoxanide has poor efficacy in immunocompromised hosts. Here, we identified and characterized a secreted dipeptidyl peptidase of Cryptosporidium parvum , CpDPP1. CpDPP1 contains an N-terminal signal peptide, an exclusion domain, and a cathepsin C-like catalytic region with conserved active-site-associated residues, consistent with a substrate-selective papain-like cysteine protease. CpDPP1 localized predominantly to the anterior end of sporozoites and was released during excystation, free-sporozoite incubation, and gliding. Parasite-derived supernatants and Pichia-expressed recombinant CpDPP1 (rCpDPP1) hydrolyzed Gly-Phe-AFC, confirming dipeptidyl peptidase activity. Active rCpDPP1 disrupted junctional E-cadherin and reduced E-cadherin abundance in Caco-2 cells, whereas heat-inactivated protein did not, linking CpDPP1 activity to epithelial barrier damage. An enzyme activity-based screen of 5000 bioactive compounds identified eight reproducible inhibitors. Hypocrellin A and fluazinam showed potent CpDPP1 inhibition (IC 50 = 4.67 and 6.82 μM, respectively), in vitro anti- C. parvum activity (EC 50 of 1.31 and 0.45 μM), in vitro selectivity indices ≥10, and protection against rCpDPP1-induced E-cadherin loss. In vivo , high-dose hypocrellin A and fluazinam reduced fecal oocyst shedding on day 3 of treatment by approximately 95.83% and 97.57%, respectively, in the chronic C. tyzzeri infection model, and on day 7 post-infection by approximately 55.39% and 52.94%, respectively, in the IFN-γ-KO C. parvum infection model, compared with vehicle controls. Treatment also reduced intestinal parasite burden, attenuated weight loss, improved survival, and ameliorated intestinal pathology. These findings identify CpDPP1 as a secreted host-interface protease linked to early infection-associated epithelial damage and support CpDPP1-directed screening as a strategy for anti-cryptosporidial inhibitor discovery.
Cryptosporidiosis is a major zoonotic diarrheal disease caused by Cryptosporidium spp. and is associated with severe diarrhea, growth faltering, malnutrition, and mortality in young children, immunocompromised individuals, and neonatal ruminants. Treatment options remain limited, and nitazoxanide has poor efficacy in immunocompromised hosts. Here, we identified and characterized a secreted dipeptidyl peptidase of Cryptosporidium parvum, CpDPP1. CpDPP1 contains an N-terminal signal peptide, an exclusion domain, and a cathepsin C-like catalytic region with conserved active-site-associated residues, consistent with a substrate-selective papain-like cysteine protease. CpDPP1 localized predominantly to the anterior end of sporozoites and was released during excystation, free-sporozoite incubation, and gliding. Parasite-derived supernatants and Pichiaexpressed recombinant CpDPP1 (rCpDPP1) hydrolyzed Gly-Phe-AFC, confirming dipeptidyl peptidase activity. Active rCpDPP1 disrupted junctional E-cadherin and reduced E-cadherin abundance in Caco-2 cells, whereas heat-inactivated protein did not, linking CpDPP1 activity to epithelial barrier damage. An enzyme activity-based screen of 5000 bioactive compounds identified eight reproducible inhibitors. Hypocrellin A and fluazinam showed potent CpDPP1 inhibition (IC50 = 4.67 and 6.82 mu M, respectively), in vitro anti-C. parvum activity (EC50 of 1.31 and 0.45 mu M), in vitro selectivity indices >= 10, and protection against rCpDPP1-induced E-cadherin loss. In vivo, high-dose hypocrellin A and fluazinam reduced fecal oocyst shedding on day 3 of treatment by approximately 95.83% and 97.57%, respectively, in the chronic C. tyzzeri infection model, and on day 7 post-infection by approximately 55.39% and 52.94%, respectively, in the IFN-gamma-KO C. parvum infection model, compared with vehicle controls. Treatment also reduced intestinal parasite burden, attenuated weight loss, improved survival, and ameliorated intestinal pathology. These findings identify CpDPP1 as a secreted host-interface protease linked to early infection-associated epithelial damage and support CpDPP1-directed screening as a strategy for anticryptosporidial inhibitor discovery.
Calcium signaling is essential for the survival of Plasmodium falciparum , yet few components of its Ca 2+ regulatory machinery have been chemically validated as antimalarial drug targets. Here, we report the structure-guided identification of small molecule inhibitors targeting a parasite specific subset of calmodulin and calmodulin-like proteins that lack close human orthologs. Virtual screening followed by biophysical validation revealed that the drugs Econazole, Carvedilol, and Deschloro-Lapatinib selectively engage three parasite calmodulin paralogs ( Pf Cam200, Pf Cam300, and Pf Cam400) and inhibit their Ca 2+ -binding activity. Direct binding was confirmed by bio-layer interferometry and calcium-binding assays, demonstrating micromolar affinities and functional inhibition. Chemical perturbation of parasite calmodulins disrupts food vacuole directed Ca 2+ trafficking, induces redistribution of intracellular Ca 2+ , and results in stage specific arrest of parasite development. Confocal imaging localizes Pf Cam200, Pf Cam300, and Pf Cam400 in proximity to the digestive vacuole transporters Pf CRT and Pf MDR1, supporting a mechanistic link between calmodulin function and vacuolar Ca 2+ homeostasis. Collectively, these findings establish parasite calmodulins as chemically tractable targets and demonstrate the utility of repurposed small molecules as probes to interrogate essential Ca 2+ -dependent pathways in malaria parasites.